Anamorelin

Cancer cachexia, as a common complication of advanced malignant tumors, can cause progressive weight loss and muscle mass loss in patients. It not only reduces the tolerance to anti-tumor therapy, but also significantly shortens the survival period, and there has been a long-term lack of targeted treatment methods in clinical practice. Anamorelin is a growth hormone secretagogue receptor agonist. By activating the ghrelin receptor, it effectively promotes the secretion of growth hormone and regulates appetite and energy metabolism. It is mainly used for the treatment of cachexia in patients with solid tumors such as non-small cell lung cancer and pancreatic cancer. It can significantly improve the weight and muscle mass of patients and improve their quality of life. It is one of the few targeted therapeutic drugs for cachexia approved in the world at present.

The global cachexia drug market size was approximately US$1.8 billion in 2023, and it is expected to continue to expand at a compound annual growth rate of 8.2% by 2030. The core driving forces are the rising global cancer prevalence and the increasing clinical attention to cachexia intervention. At present, the market competition pattern of anamorelin is relatively concentrated, with the original research product occupying the main market share. There are no approved generic drugs in China yet, and only a few enterprises are in the stage of generic drug R&D and declaration, leaving a large gap in the market supply side.

The original research enterprise of anamorelin is Helsinn Healthcare in Switzerland, and the original research trade name is Adlumiz. Its compound patent in Japan expired in 2021, and the core patent in China expired in 2024. The main dosage form of the original research product is oral tablet, with a specification of 50 mg per tablet. It has been included in the reference preparation catalogs of Japan's PMDA and the US FDA, and has not yet been included in China's *Catalogue of Chemical Drugs*. There are no anamorelin preparations approved for marketing in China, and the API registration platform has not yet publicized a valid API registration number in status A. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for anamorelin, and most of the products are in stock. For in-stock products, orders placed before 16:00 will be shipped on the same day. The products fully comply with the requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can provide stable and compliant reference standard support for the R&D and quality control stages of APIs and preparations.